Search Results 21-30 of 16564 for B cell lymphomas

  1. Axi-cel treatment for B-cell lymphoma provides real-world outcomes comparable to ZUMA-1 trial data - Mayo Clinic

    In a study of axicabtagene ciloleucel (axi-cel) CAR-T cell therapy for relapsed or refractory aggressive B-cell lymphoma, 30-day responses were comparable ...

  2. Lymphoma Patients Event-Free Two Years after Diagnosis have a Normal Life Expectancy

    — Feb. 18, 2014 — Newly-diagnosed patients with diffuse large B cell lymphoma (DLBCL) who do not experience any cancer-related outcome events for two years ...

  3. A Study to Compare Tisagenlecleucel vs. Standard of Care in Adult Patients with Aggressive B-cell Non-Hodgkin Lymphoma - Mayo Clinic

    A Study to Compare Tisagenlecleucel vs. Standard of Care in Adult Patients with Aggressive B-cell Non-Hodgkin Lymphoma · Share · Facebook · Twitter.

  4. Lymphoma - Diagnosis and treatment - Mayo Clinic

    Low-grade lymphomas have an advantage in that they can take a very long ... B-Cell lymphoma. Journal of Hematopathology. 2019; doi:10.1007/s12308-019 ...

  5. Non-Hodgkin's lymphoma - Doctors and departments - Mayo Clinic

    Developing the Lymph2Cx genetic test to help guide the diagnosis and treatment of people with diffuse large B-cell lymphoma, the most common type of non- ...

  6. Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) - Mayo Clinic

    Clinical Trials · Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) · More about research at Mayo Clinic · Mayo ...

  7. GEN3013, Epcoritamab Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma EPCORE™ NHL-1 - Mayo Clinic

    Clinical Trials · GEN3013, Epcoritamab Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma EPCORE™ NHL-1 · More about research at Mayo ...

  8. Advancement in CAR-T cell therapy for resistant B cell cancers - Mayo Clinic

    CAR -T cell therapy has shown potential in achieving remission in some B-cell lymphomas and leukemias. Yet, challenges persist with cancer relapsing in ...

  9. Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy - Mayo Clinic

    Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy · Overview · Participation ...

  10. Non Hodgkin's Clinical Trials - Mayo Clinic Research

    It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with mantle cell lymphoma. Venetoclax ...